logo
Plus   Neg
Share
Email

Sanofi, GSK To Refine Antigen Formulation Of COVID-19 Vaccine Based On Initial Phase 1/2 Study

Sanofi and GlaxoSmithKline announced the initiation of a new phase 2 study to select the most appropriate antigen dosage for phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate. The companies noted that the new phase 2 study will enable them to identify the final vaccine formulation for adults of all ages. The trial will consist of equal numbers of adults 18 to 59 years and those 60 years and above.

In December, phase 1/2 study results showed an immune response comparable to patients who had recovered from COVID-19 in adults aged 18 to 49 years, but a lower immune response in older adults.

The companies anticipate to further progress this vaccine candidate to phase 3 in second quarter of 2021, if the phase 2 study is successful. The vaccine is projected to be available in fourth quarter of 2021, if approved.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walmart Inc. has launched a nationwide drive to boost COVID-19 vaccination rates by reaching out to more residents in vulnerable communities. The retail giant will organize a series of community events at 43 locations in 18 states to administer the COVID-19 vaccine. Walmart said it plans to continue these new events over the next several weeks as vaccine allocations allow. Pfizer Inc. (PFE) and OPKO Health Inc. (OPK) announced Friday that the European Medicines Agency or EMA has validated for review the Marketing Authorization Application for somatrogon. Pfizer expects a decision from the European Commission in 2022. The company said somatrogon is a long-acting recombinant... German telecom giant Deutsche Telekom AG reported Friday strong growth in fourth-quarter profit mainly driven by T-Mobile US results following the takeover of the competitor Sprint. Looking ahead for fiscal 2021, the company projects higher adjusted EBITDA AL, a key earnings metric.
Follow RTT